NextCure, Inc. Profile Avatar - Palmy Investing

NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is i…

Biotechnology
US, Beltsville [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

NextCure, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

NextCure, Inc. can't present revenue by segment

End of NXTC's Analysis
CIK: 1661059 CUSIP: 65343E108 ISIN: US65343E1082 LEI: - UEI: -
Secondary Listings
NXTC has no secondary listings inside our databases.